PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation

Marianne R Spalinger; Michael Scharl

doi:10.1080/23723556.2018.1465013

PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation

Mol Cell Oncol. 2018 Jun 6;5(4):e1465013. doi: 10.1080/23723556.2018.1465013. eCollection 2018.

Authors

Marianne R Spalinger¹, Michael Scharl¹

Affiliation

¹ Department for Gastroenterology and Hepatology, University Hospital Zurich, and University of Zurich, Zurich, Switzerland.

Abstract

We have recently demonstrated that macrophage-specific loss of Protein tyrosine phosphatase non-receptor type 2 (PTPN2) promotes inflammasome activation, resulting in protection from colorectal cancer. Here we place these findings in context with the role of inflammasomes in colorectal carcinoma, and with a recent study indicating that PTPN2-silencing promotes anti-cancer immunotherapy.

Keywords: Biology of malignant cells; Biology of the tumor stroma; Colitis-associated cancer; IFN-gamma; Inflammasome; Mechanisms of oncogenesis and tumor progression; PTPN2; TC-PTP; Tumor-stroma interactions; Tyrosine Phosphatase.